Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced the frequency of cataplexy ...
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) ...
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy
Axsome Therapeutics (AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with cataplexy ...
Louis Eperjesi Buys 21,000 Shares of Accsys Technologies PLC (LON:AXS) Stock
Accsys Technologies PLC (LON:AXS – Get Free Report) insider Louis Eperjesi bought 21,000 shares of the company’s stock in a ...
Axsome Therapeutics announces AXS-12 achieves primary endpoint in ENCORE
Axsome Therapeutics (AXSM) announced that AXS-12 achieved the primary endpoint in the ENCORE Phase 3 trial, demonstrating a statistically ...
Business Insider5d
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo ...
Why Is Axis Capital (AXS) Up 19.9% Since Last Earnings Report?
Axis Capital (AXS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stockhouse5d
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo ...